The Revivent TC System (BioVentrix Inc, San Ramon, CA) enables a less invasive approach for left ventricular reshaping and scar exclusion in selected patients with ischemic cardiomyopathy. Although the system is designed to improve quality of life and to promote reverse remodeling, patients can still progress to end-stage heart failure requiring advanced therapies. This report describes a case of left ventricular assist device surgery in a patient 16 months after Revivent System implantation. The planning process and surgical technique proved to be complex. This case report can help provide guidance to advanced heart failure teams who encounter patients with the Revivent System who require left ventricular assist device support.
Bibliographical noteFunding Information:
Dr Wechsler serves as national co-principal investigator for the ALIVE trial. Drs John and Alexy serve as site principal investigators for the ALIVE trial at the University of Minnesota.
© 2021 The Society of Thoracic Surgeons
PubMed: MeSH publication types
- Case Reports